Novo Holdings to acquire Ritedose

Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to acquire Ritedose from AGIC Capital and Humanwell.

Founded in 1995 and headquartered in Columbia, S.C., The Ritedose Corporation (“Ritedose”) is a leading sterile pharmaceutical manufacturer, specialising in the use of blow-fill-seal (BFS) technology. Ritedose provides outsourced development and manufacturing of ophthalmology drugs, respiratory drugs, and vaccines. In addition, Ritedose develops and markets its own portfolio of generic drugs and is an emerging player in the outsourced sterile compounding market focusing on medically necessary drugs that are in short supply. Ritedose customers range from small start-ups and large pharmaceutical companies to wholesalers, retail pharmacies and hospital systems. Today, the company employs more than 400 people and is led by Chief Executive Officer Jody Chastain, who will continue to run the company under Novo Holdings’ ownership.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH